Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales were up 5% in the quarter to $11.4 billion.

By: Contract Pharma

Contract Pharma Staff

Financial Report: Johnson & Johnson
3Q Revenues: $21.1 billion (+2%)
3Q Earnings: $3.6 billion (+103%)
YTD Revenues: $60.1 billion (-2%)
YTD Earnings: $13.0 billion (+17%)
Comments: Pharmaceutical sales were $11.4 billion in the quarter, up 5%, driven by DARZALEX (+44% to $1.1 billion) for the treatment of multiple myeloma, STELARA (+15% to $1.9 billion) for the treatment of a number of immune-mediated inflammatory diseases, IMBRUVICA (+12% to $1.0 billion) for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (+9% to $926 million) for the treatment of schizophrenia, OPSUMIT (+13% to $392 million) for the treatment of pulmonary arterial hypertension to delay disease progression, UPTRAVI (+24% to $260 million) to treat pulmonary arterial hypertension and reduce hospitalization, and ERLEADA ($206 million, up from $86 million) for the treatment of prostate cancer. This growth was partially offset by the negative impact of COVID-19 as well as biosimilar and generic competition, with declines primarily in REMICADE (-19% to $921 million) and ZYTIGA (-20% to $590 million).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters